Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979546677> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2979546677 abstract "Abstract Background Palbociclb is an orally available selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) that is indicated for patients with hormone receptor-positive HER2-negative advanced or recurrent breast cancer with 3 weeks on/1 week off schedule. Previous report showed that elevated serum creatinine (Scr) was only 2.0% in frequency for all grade, without cases of grade 3 or more. Anecdotal episode of declined eGFR (implying elevated Scr) seems to be more frequent in daily clinical practice; however, the actual frequency of declined eGFR and its impact on severe toxicity has not been determined yet. Objective To investigate the frequency of declined eGFR in patients treated with palbociclib and to determine the association between declined eGFR and severe toxicity. Methods Consecutive patients treated with palbociclib at National Cancer Center Hospital East between December 1 2017 and May 31 2018 were retrospectively investigated. Patient characteristics, eGFR at cycle 1 day1 (C1D1) and C1D15, C2D1, C2D15, and C3D1 of palbociclib, grade 4 neutropenia, treatment discontinuation or interruption caused by toxicity were retrieved from medical records. The frequency of declined eGFR and its correlation with severe toxicity were analyzed. Results A total of 42 patients were included. Median age was 65 years (range 43-80), and 41 cases were female. Median eGFR at the start of palbociclib was 76 mL/min/1.73m2, which declined 12.5 in median (range 3.0-39.0) on C1D15. At C2D1, eGFR was recovered (change in median -3 mL/min/1.73m2; range -17.0 - +19.0). Declined eGFR was not correlated significantly with either grade 4 neutropenia or treatment discontinuation. Conclusions While eGFR was declined by median of 12.5 mL/min/1.73m2 with palbociclib administration on C1D15, eGFR recovered to the baseline by drug interruption. Declined eGFR was not correlated with severe toxicity such as grade 4 neutropenia or toxicities leading to treatment discontinuation." @default.
- W2979546677 created "2019-10-18" @default.
- W2979546677 creator A5000514150 @default.
- W2979546677 creator A5003760237 @default.
- W2979546677 creator A5014625956 @default.
- W2979546677 creator A5015213436 @default.
- W2979546677 creator A5015469948 @default.
- W2979546677 creator A5026686013 @default.
- W2979546677 creator A5030591160 @default.
- W2979546677 creator A5036656018 @default.
- W2979546677 creator A5058220340 @default.
- W2979546677 creator A5064272098 @default.
- W2979546677 creator A5064842599 @default.
- W2979546677 creator A5079504645 @default.
- W2979546677 creator A5085102101 @default.
- W2979546677 date "2019-10-01" @default.
- W2979546677 modified "2023-09-24" @default.
- W2979546677 title "A study of the renal hypofunction and accompanying adverse events in breast cancer patients treated with palbociclb" @default.
- W2979546677 doi "https://doi.org/10.1093/annonc/mdz338.104" @default.
- W2979546677 hasPublicationYear "2019" @default.
- W2979546677 type Work @default.
- W2979546677 sameAs 2979546677 @default.
- W2979546677 citedByCount "0" @default.
- W2979546677 crossrefType "journal-article" @default.
- W2979546677 hasAuthorship W2979546677A5000514150 @default.
- W2979546677 hasAuthorship W2979546677A5003760237 @default.
- W2979546677 hasAuthorship W2979546677A5014625956 @default.
- W2979546677 hasAuthorship W2979546677A5015213436 @default.
- W2979546677 hasAuthorship W2979546677A5015469948 @default.
- W2979546677 hasAuthorship W2979546677A5026686013 @default.
- W2979546677 hasAuthorship W2979546677A5030591160 @default.
- W2979546677 hasAuthorship W2979546677A5036656018 @default.
- W2979546677 hasAuthorship W2979546677A5058220340 @default.
- W2979546677 hasAuthorship W2979546677A5064272098 @default.
- W2979546677 hasAuthorship W2979546677A5064842599 @default.
- W2979546677 hasAuthorship W2979546677A5079504645 @default.
- W2979546677 hasAuthorship W2979546677A5085102101 @default.
- W2979546677 hasConcept C121608353 @default.
- W2979546677 hasConcept C126322002 @default.
- W2979546677 hasConcept C126894567 @default.
- W2979546677 hasConcept C141071460 @default.
- W2979546677 hasConcept C143998085 @default.
- W2979546677 hasConcept C197934379 @default.
- W2979546677 hasConcept C2775930923 @default.
- W2979546677 hasConcept C2777063308 @default.
- W2979546677 hasConcept C2778715236 @default.
- W2979546677 hasConcept C2779744173 @default.
- W2979546677 hasConcept C2780306776 @default.
- W2979546677 hasConcept C29730261 @default.
- W2979546677 hasConcept C530470458 @default.
- W2979546677 hasConcept C71924100 @default.
- W2979546677 hasConcept C90924648 @default.
- W2979546677 hasConceptScore W2979546677C121608353 @default.
- W2979546677 hasConceptScore W2979546677C126322002 @default.
- W2979546677 hasConceptScore W2979546677C126894567 @default.
- W2979546677 hasConceptScore W2979546677C141071460 @default.
- W2979546677 hasConceptScore W2979546677C143998085 @default.
- W2979546677 hasConceptScore W2979546677C197934379 @default.
- W2979546677 hasConceptScore W2979546677C2775930923 @default.
- W2979546677 hasConceptScore W2979546677C2777063308 @default.
- W2979546677 hasConceptScore W2979546677C2778715236 @default.
- W2979546677 hasConceptScore W2979546677C2779744173 @default.
- W2979546677 hasConceptScore W2979546677C2780306776 @default.
- W2979546677 hasConceptScore W2979546677C29730261 @default.
- W2979546677 hasConceptScore W2979546677C530470458 @default.
- W2979546677 hasConceptScore W2979546677C71924100 @default.
- W2979546677 hasConceptScore W2979546677C90924648 @default.
- W2979546677 hasLocation W29795466771 @default.
- W2979546677 hasOpenAccess W2979546677 @default.
- W2979546677 hasPrimaryLocation W29795466771 @default.
- W2979546677 isParatext "false" @default.
- W2979546677 isRetracted "false" @default.
- W2979546677 magId "2979546677" @default.
- W2979546677 workType "article" @default.